Here’s what you need to know:
1. The company experienced an 8.5 percent increase in year-over-year revenues, topping $281.6 million.
2. NuVasive’s second quarter income sits at $11.5 million,or $0.22 per share.
3. NuVasive reported a gross profit of $204.5 million for the second quarter.
4. For full-year 2018, the company expects to see revenues range between $1.095 billion and $1.105 billion, reflecting a 6.7 percent to 7.6 percent year-over-year increase.
5. NuVasive anticipates its diluted earnings per share to range between $2.37 and $2.40.
To view the full report, click here.
More articles on devices and implants:
Dr. Alexis Waguespack performs surgery with Mobi-C Cervical Disc: 3 insights
6 key players in the global thoracolumbar spine devices market
Spine Wave raises $5.3M in funding: 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
